Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2011

01-12-2011 | Research Article

Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma

Authors: Xiao-Nan Sun, Wei-Guo Cao, Xin Wang, Qi Wang, Ben-Xing Gu, Qi-Chu Yang, Jian-Bin Hu, Hai Liu, Shu Zheng

Published in: Tumor Biology | Issue 6/2011

Login to get access

Abstract

The purpose of this study was to evaluate the value of vascular endothelial growth factor-A (VEGF-A) expression and other confirmed prognostic factors in predicting clinical outcomes after the resection of gallbladder carcinoma (GBC). Between January 1999 and January 2006, a total of 84 consecutive and non-selected patients who underwent resection for GBC were retrospectively reviewed. Of the 84 patients studied, 45 cases (53.6%) exhibited high expression of VEGF-A and were placed into the high expression group. The 14 cases (16.7%) that showed no VEGF expression and the 25 cases (29.7%) that had lower VEGF-A levels were pooled into the low expression group (46.4%). There was a relationship between VEGF-A status and pM stage (P = 0.027) as well as histologic differentiation (P < 0.001). In univariate analysis by log-rank test, ECOG performance status, CA 19-9, pN stage, pM stage, histologic differentiation, and VEGF-A expression were significant prognostic factors (P = 0.015, 0.001, 0.020, <0.001, 0.040, and <0.001, respectively). Multivariate analysis revealed that pN status and VEGF-A expression maintained independent prognostic influence on overall survival (P < 0.001 and P = 0.013, respectively). VEGF-A expression has a positive correlation with pM stage and histologic differentiation. pN status and VEGF-A expression were independent prognostic factors of overall survival in patients with resected GBC.
Literature
1.
2.
Furuse J. Postoperative adjuvant treatments for biliary tract cancer. J Hepatobiliary Pancreat Surg. 2008;15:463–7.PubMedCrossRef
3.
de Aretxabala X, Roa I, Berrios M, Hepp J, Gallardo J, Cordova A, et al. Chemoradiotherapy in gallbladder cancer. J Surg Oncol. 2006;93:699–704.PubMedCrossRef
4.
Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008;98:485–9.PubMedCrossRef
5.
Ito H, Matros E, Brooks DC, Osteen RT, Zinner MJ, Swanson RS, et al. Treatment outcomes associated with surgery for gallbladder cancer: a 20-year experience. J Gastrointest Surg. 2004;8:183–90.PubMedCrossRef
6.
Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo clinic experience. Int J Radiat Oncol Biol Phys. 2009;75:150–5.PubMedCrossRef
7.
Cho SY, Kim SH, Park SJ, Han SS, Kim YK, Lee KW, et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol. 2010;102:87–93.PubMedCrossRef
8.
Murakami Y, Uemura K, Hayasidani Y, Sudo T, Hashimoto Y, Ohge H, et al. Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection. Dig Dis Sci. 2009;54:1360–4.PubMedCrossRef
9.
Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala Nirag C, Callens T, Messiaen L, et al. Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010;1:76–89.
10.
Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg. 2001;193:380–3.PubMedCrossRef
11.
Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Sivridis E. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol. 2003;29:879–83.PubMedCrossRef
12.
Giatromanolaki A, Sivridis E, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, et al. Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol. 2006;94:242–7.PubMedCrossRef
13.
14.
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27.PubMedCrossRef
15.
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–39.PubMed
16.
Okita S, Kondoh S, Shiraishi K, Kaino S, Hatano S, Okita K. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol. 1998;12:1013–8.PubMed
17.
Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds) (2002). American Joint Committee on Cancer Staging Manual. 6th ed. Springer, New York 139–144
18.
Kokudo N, Makuuchi M, Natori T, Sakamoto Y, Yamamoto J, Seki M, et al. Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg. 2003;138:741–50.PubMedCrossRef
19.
Tsukada K, Kurosaki I, Uchida K, Shirai Y, Oohashi Y, Yokoyama N, et al. Lymph node spread from carcinoma of the gallbladder. Cancer. 1997;80:661–7.PubMedCrossRef
20.
Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 1999;19:2257–60.PubMed
21.
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol. 1995;177:275–83.PubMedCrossRef
22.
Volm M, Koomägi R, Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. 1996;16:213–7.PubMed
23.
Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998;4:3017–24.PubMed
24.
Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000;60:3088–95.PubMed
25.
Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiuchi T, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet -derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119:227–35.PubMedCrossRef
26.
Maeda K, Kang SM, Ogawa M, Onoda N, Sawada T, Nakata B, et al. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer. 1997;74:545–50.PubMedCrossRef
27.
Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, et al. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res. 1998;4:429–34.PubMed
28.
Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79:1553–63.PubMedCrossRef
29.
Seki S, Fujiwara M, Matsuura M, Fujita S, Ikeda H, Asahina I, et al. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. Oral Oncol. 2011;47:588–93.PubMedCrossRef
30.
Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg. 1996;224:639–46.PubMedCrossRef
31.
Yamaguchi K, Nagino M, Oda K, Kamiya K, Uesaka K, Nimura Y. Perineural invasion has a negative impact on survival of patients with gallbladder cancer. Br J Surg. 2002;89:1130–6.PubMedCrossRef
32.
Fong Y, Jamagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000;232:557–69.PubMedCrossRef
33.
Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4:695–706.PubMedCrossRef
34.
Kayahara M, Nagakawa T, Nakagawara H, Kitagawa H, Ohta T. Prognostic factors for gallbladder cancer in Japan. Ann Surg. 2008;248:807–14.PubMedCrossRef
35.
Lowenfels AB. Gallstones and glaciers: the stone that came in from the cold. Lancet. 1988;18:1385–6.CrossRef
36.
Lowenfels AB, Maisonneuve P, Boyle P, Zatonski WA. Epidemiology of gallbladder cancer. Hepatogastroenterology. 1999;46:1529–32.PubMed
37.
Liu Y, Qiu Y, Zhang X, Tian Y, Huang D, Zhou X, et al. The expression and correlation of HMGB1 and VEGF protein in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011;25:265–9.PubMed
38.
Czito BG, Hurwitz HI, Clough RW, Tyler DS, Morse MA, Clary BM, et al. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys. 2005;62:1030–4.PubMedCrossRef
39.
Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:167–75.PubMedCrossRef
Metadata
Title
Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma
Authors
Xiao-Nan Sun
Wei-Guo Cao
Xin Wang
Qi Wang
Ben-Xing Gu
Qi-Chu Yang
Jian-Bin Hu
Hai Liu
Shu Zheng
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0221-2

Other articles of this Issue 6/2011

Tumor Biology 6/2011 Go to the issue

Research Article

Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis

Research Article

Evaluation of the phenotype pattern of macrophages isolated from malignant and non-malignant pleural effusions

Research Article

Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients

Research Article

SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer

Research Article

NADPH oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy

Research Article

The significance of expression of autophagy-related gene Beclin, Bcl-2, and Bax in breast cancer tissues
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits